Basic HTML Version
Cost Containment
Although the government is not likely to adopt reference pricing
in U.S., insurers and other payers are considering versions of
reference pricing to contain costs
In response to pressures on the product life cycle, pharmas
are applying for patent extensions while developing drug
reformulations to extend market exclusivity
Confidential: For Internal Use Only
ENV I RONMENTAL OVE RV I EW
COS T CONTA I NMENT 43